IMVT News and Press, Immunovant Inc. From 03/06/23

2023-03-06 17:07:59 ET Summary Immunovant's lead drug, batoclimab, is one of many FcRn antagonists, either approved or in development, for the treatment of autoimmune diseases, including myasthenia gravis (MG). In batoclimab clinical trials by Immunovant, safety concerns emerged w...

Summary argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher went to waste. Getting subcutaneous efgartigimod to market is important as ...

Immunovant press release ( NASDAQ: IMVT ): Q3 GAAP EPS of -$0.49 misses by $0.09 . As of December 31, 2022, Immunovant’s cash and cash equivalents totaled $432.6M, which is expected to fund operations into the second half of calendar year 2025. For further details...

A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023 A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in chronic inflammatory demyelinating polyneuropathy (CIDP) were initiated, as expected P...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The stock market got crushed in 2022. It was a nasty year for most investors.  But what if I told you that amid 2022’s financial market turmoil, there was a quantitative trading system that was regularly pi...

Summary Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin le...

Immunovant, Inc. ( NASDAQ: IMVT ) continued a five-day winning streak on Tuesday as Wells Fargo upgraded it to Overweight from Equal Weight, naming the autoimmune drug developer as a top pick in its 2023 SMID cap biotech preview. Derek Archila and analysts see positive readthrough for...

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a f...

Immunovant press release ( NASDAQ: IMVT ): Q3 GAAP EPS of -$0.41. Financial Highlights for Fiscal Second Quarter Ended September 30, 2022:R&D Expenses: Research and development expenses were $37.7 million for the three months ended September 30, 2022, compared to $21.4...

IMVT-1402, a next generation, subcutaneously administered, neonatal fragment crystallizable receptor (FcRn) inhibitor unveiled New development programs for batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease announced Phase 3 t...